<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03303313</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-CC5-004</org_study_id>
    <nct_id>NCT03303313</nct_id>
  </id_info>
  <brief_title>A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome</brief_title>
  <official_title>A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients With Atypical Hemolytic Uremic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
      Cemdisiran in patients with aHUS.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study terminated early due to lack of enrollment.
  </why_stopped>
  <start_date type="Actual">September 19, 2017</start_date>
  <completion_date type="Actual">September 12, 2018</completion_date>
  <primary_completion_date type="Actual">September 12, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of Cemdisiran on platelet count</measure>
    <time_frame>Week 32</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of Cemdisiran on hematological response as measured by platelet count</measure>
    <time_frame>after 32 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of Cemdisiran on hematological response as measured by lactate dehydrogenase (LDH)</measure>
    <time_frame>after 32 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of Cemdisiran on hematological response as measured by rescue plasma therapy</measure>
    <time_frame>after 32 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of Cemdisiran on LDH response as measured by LDH</measure>
    <time_frame>after 32 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of Cemdisiran on LDH response as measured by rescue plasma therapy</measure>
    <time_frame>after 32 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of Cemdisiran on complete Thrombotic microangiopathy (TMA) response as measured by platelet count</measure>
    <time_frame>after 32 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of Cemdisiran on complete Thrombotic microangiopathy (TMA) response as measured by LDH</measure>
    <time_frame>after 32 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of Cemdisiran on complete Thrombotic microangiopathy (TMA) response as measured by serum creatinine levels</measure>
    <time_frame>after 32 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of Cemdisiran on complete Thrombotic microangiopathy (TMA) response as measured by rescue plasma therapy</measure>
    <time_frame>after 32 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of Cemdisiran on serum creatinine levels</measure>
    <time_frame>up to 84 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of Cemdisiran on estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>up to 84 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of Cemdisiran on adverse events (AEs)</measure>
    <time_frame>up to 108 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Atypical Hemolytic Uremic Syndrome</condition>
  <arm_group>
    <arm_group_label>Cemdisiran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cemdisiran</intervention_name>
    <description>Subcutaneous (sc) injection of Cemdisiran</description>
    <arm_group_label>Cemdisiran</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing to provide written informed consent and to comply with the study requirements

          2. Age 18 years or older

          3. Clinical diagnosis of primary aHUS

          4. Clinical thrombotic microangiopathy (TMA) activity

          5. Women of child-bearing potential must have a negative pregnancy test, cannot be breast
             feeding, and must be willing to use a highly effective method of contraception

          6. Previously vaccinated with meningococcal group ACWY conjugate vaccine and
             meningococcal group B vaccine or willingness to receive these vaccinations

          7. ADAMTS13 &gt;10% or other proven aHUS-associated mutation

        Exclusion Criteria:

          1. Clinically significant abnormal laboratory results

          2. Positive Shiga toxin producing Escherichia coli test at Screening

          3. Suspected secondary aHUS, in the opinion of the Investigator (unless there is a
             documented aHUS-associated genetic mutation)

          4. Positive direct Coombs test

          5. Patients who have received hemodialysis for &gt;3 months

          6. Bone marrow transplant recipients

          7. Organ transplant recipients, except for kidney transplant recipients with primary aHUS
             (confirmed by known genetic mutation and kidney biopsy)

          8. Known history or evidence of systemic lupus erythematosus or antiphospholipid antibody
             syndrome

          9. History of multiple drug allergies or history of allergic reaction to an
             oligonucleotide or GalNAc

         10. Malignancy (except for non-melanoma skin cancers, cervical in-situ carcinoma, breast
             ductal carcinoma in situ, or stage 1 prostate carcinoma) within the last 5 years

         11. Patients with a poor prognosis that is expected to limit their life expectancy to less
             than 3 months, in the opinion of the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nader Najafian, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Skopje</city>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Canada</country>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Moldova, Republic of</country>
    <country>Serbia</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 25, 2017</study_first_submitted>
  <study_first_submitted_qc>October 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2017</study_first_posted>
  <last_update_submitted>September 27, 2018</last_update_submitted>
  <last_update_submitted_qc>September 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RNAi therapeutic</keyword>
  <keyword>Atypical Hemolytic Uremic Syndrome</keyword>
  <keyword>Hemolysis</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Renal insufficiency</keyword>
  <keyword>Thrombotic Microangiopathy</keyword>
  <keyword>aHUS</keyword>
  <keyword>TMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azotemia</mesh_term>
    <mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
    <mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

